Pozen, Inc. (POZN) is one of our top-picks for small-cap biotech. We see the fundamentals as strong and the valuation as low. We are pleased to see the NDA for Vimovo (PN-400) filed and now accepted by the U.S. FDA. FDA acceptance earned Pozen a $10 million milestone from AstraZeneca in August.

We expect sales of Treximet to ramp in the coming quarters now that the groundwork has been laid. And finally, phase III trials on the very exciting PA program should start in the fall.

The company is financially well positioned and fundamentally strong with respect to the pipeline.

We recommend being buyers at this level.

Zacks Investment Research
View original at: Zacks.com News Feed

1. (CVX) Chevron Corp.- Bull of the DayChevron Corp. (CVX) reported better-than-expected second-quarter 2009 EPS of $1.10, surpassing the Zacks Consensus Estimate...
2. (POZN) Pozen Inc.: Stock of the Dayby Katharine Schildt, Assistant Editor, The Oxford Club This Small-Cap Biotech Just Hit its Stride...

Search Posts by Tag: POZEN Inc | POZN | Drug Manufacturers - Other | Healthcare

RSS Feeds by Tag: POZEN Inc | POZN | Drug Manufacturers - Other | Healthcare |

Other Posts by: vitalstocks | RSS Feed for this author